0001209191-15-053402.txt : 20150615 0001209191-15-053402.hdr.sgml : 20150615 20150615173153 ACCESSION NUMBER: 0001209191-15-053402 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150611 FILED AS OF DATE: 20150615 DATE AS OF CHANGE: 20150615 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: El-Hibri Fuad CENTRAL INDEX KEY: 0001380185 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 15932539 MAIL ADDRESS: STREET 1: 2273 RESEARCH BLVD, SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-06-11 0 0001367644 Emergent BioSolutions Inc. EBS 0001380185 El-Hibri Fuad 2273 RESEARCH BLVD., SUITE 400 ROCKVILLE MD 20850 1 1 1 0 Chairman Common Stock 2015-06-11 4 S 0 30000 32.2641 D 1965632 D Common Stock 2015-06-12 4 S 0 15068 32.0301 D 1950564 D Common Stock 2015-06-15 4 S 0 368 32.00 D 1950196 D Common Stock 2350331 I By Intervac, L.L.C. Common Stock 1524155 I By Biovac, L.L.C. All sales listed on this Form 4 were made by the Reporting Person pursuant to a plan, adopted on May 11, 2015, that is intended to comply with Rule 10b5-1(c) under the Exchange Act. The shares of Common Stock were sold at prices ranging from $31.99 to $32.62. Upon request, the Reporting Person will provide to the SEC staff, the Issuer and any security holder of the Issuer the full information regarding the separate sales prices. The shares of Common Stock were sold at prices ranging from $32.01 to $32.18. Upon request, the Reporting Person will provide to the SEC staff, the Issuer and any security holder of the Issuer the full information regarding the separate sales prices. Mr. El-Hibri's holdings through Intervac, L.L.C. include 1,638,403 shares of Common Stock held by Mr. El-Hibri and his wife, as tenants by the entirety, through their 37.7% equity interest in Intervac, L.L.C.; 127,721 shares held by Mr. El-Hibri's wife; and 584,207 shares held by trusts indirectly controlled by Mr. El-Hibri or his wife. Mr. El-Hibri disclaims beneficial ownership, for purposes of Section 16 of the Exchange Act or otherwise, of those shares held solely by his wife and those shares held by the trusts. Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,524,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 1,359,546 shares. /s/ Carl A. Valenstein, attorney-in-fact 2015-06-15